Monte Rosa Therapeutics (GLUE) financial statements
Monte Rosa Therapeutics reported revenue of $124M in fiscal 2025, up 63.5% a year over 1 years.
Net income was -$39M.
Free cash flow was -$27M.
The diluted share count rose 5376% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Monte Rosa Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $76M | $124M |
| Research and development | $24M | $57M | $85M | $111M | $122M | $142M |
| Selling, general and admin | $4M | $16M | $27M | $32M | $35M | $36M |
| Operating income | -$28M | -$73M | -$112M | -$143M | -$81M | -$54M |
| Pre-tax income | -$10M | -$10M | -$109M | -$135M | -$70M | -$40M |
| Income tax | — | — | $0 | $338,000 | $3M | -$1M |
| Net income | -$36M | -$74M | -$109M | -$135M | -$73M | -$39M |
| EPS (diluted) | -$23.65 | -$2.96 | — | — | — | — |
| Diluted shares | 2M | 25M | 47M | 51M | 74M | 83M |
| Operating margin | — | — | — | — | -107.3% | -43.8% |
| Net margin | — | — | — | — | -96.1% | -31.2% |
Balance sheet
Fiscal years, from Monte Rosa Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $42M | $346M | $55M | $128M | $224M | $377M |
| Total current assets | $44M | $349M | $276M | $236M | $377M | $393M |
| Property, plant and equipment | $5M | $12M | $27M | $34M | $29M | $26M |
| Total assets | $49M | $366M | $342M | $304M | $439M | $449M |
| Total current liabilities | $29M | $17M | $26M | $47M | $157M | $64M |
| Total liabilities | $30M | $19M | $71M | $125M | $216M | $216M |
| Shareholders' equity | -$49M | $348M | $271M | $179M | $223M | $233M |
| Net debt | -$42M | -$346M | -$55M | -$128M | -$224M | -$130M |
Cash flow
Fiscal years, from Monte Rosa Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$23M | -$59M | -$92M | -$44M | $42M | -$23M |
| Capital spending | $3M | $10M | $13M | $19M | $4M | $5M |
| Free cash flow | -$26M | -$69M | -$105M | -$63M | $38M | -$27M |
| Stock-based compensation | $354,000 | $5M | $12M | $17M | $18M | $19M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 |
| Free cash flow margin | — | — | — | — | 50.3% | -22.2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for GLUE.
Open GLUE in InvestinglyQuestions
What was Monte Rosa Therapeutics's revenue in 2025?
$124M in fiscal 2025, from its 10-K filing.
How much free cash flow does Monte Rosa Therapeutics generate?
-$27M in fiscal 2025 (operating cash flow minus capital spending).
From Monte Rosa Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.